Holen Sie sich die Stockscreener-App
3.96
2.06%
0.08
Vorhandelsmarkt:
4.00
0.04
+1.01%
Schlusskurs vom Vortag:
$3.88
Offen:
$3.85
24-Stunden-Volumen:
649.60K
Relative Volume:
0.67
Marktkapitalisierung:
$251.71M
Einnahmen:
$157.08M
Nettoeinkommen (Verlust:
$-70.36M
KGV:
-3.5624
EPS:
-1.1116
Netto-Cashflow:
$-71.69M
1W Leistung:
+2.33%
1M Leistung:
-6.82%
6M Leistung:
+145.96%
1J Leistung:
+189.05%
1-Tages-Spanne:
$3.85
$4.07
1-Wochen-Bereich:
$3.81
$4.245
52-Wochen-Spanne:
$1.185
$4.6401
Macrogenics Inc Stock (MGNX) Company Profile
Firmenname
Macrogenics Inc
Sektor
Branche
Telefon
301-251-5172
Adresse
9704 MEDICAL CENTER DRIVE, Rockville, MD
Compare MGNX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MGNX
Macrogenics Inc
|
3.96 | 262.52M | 157.08M | -70.36M | -71.69M | -1.1116 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Macrogenics Inc Stock (MGNX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-10 | Hochstufung | B. Riley Securities | Neutral → Buy |
| 2025-09-17 | Fortgesetzt | Barclays | Overweight |
| 2024-11-07 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-08-01 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-07-31 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2024-07-31 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-05-10 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-05-10 | Herabstufung | Stifel | Buy → Hold |
| 2024-05-10 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-04-26 | Eingeleitet | B. Riley Securities | Buy |
| 2024-04-09 | Hochstufung | TD Cowen | Hold → Buy |
| 2024-03-04 | Bestätigt | BTIG Research | Buy |
| 2024-02-14 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-12-20 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-11-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-03-17 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-11-22 | Herabstufung | Cowen | Outperform → Market Perform |
| 2022-11-14 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-07-18 | Herabstufung | SMBC Nikko | Outperform → Neutral |
| 2022-07-11 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-05-04 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-02-28 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-02-11 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-02-04 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-11-17 | Fortgesetzt | Guggenheim | Buy |
| 2021-10-19 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-12 | Hochstufung | Barclays | Underweight → Overweight |
| 2020-12-22 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-08-03 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-06-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-05-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-04 | Eingeleitet | Barclays | Underweight |
| 2019-12-19 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-12-18 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-11-21 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2019-11-20 | Fortgesetzt | Guggenheim | Neutral |
| 2019-05-03 | Hochstufung | Wedbush | Neutral → Outperform |
| 2019-04-12 | Eingeleitet | Guggenheim | Neutral |
| 2019-02-07 | Hochstufung | Citigroup | Sell → Buy |
| 2019-02-07 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-02-06 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2019-02-04 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-12-10 | Herabstufung | Raymond James | Outperform → Underperform |
| 2018-09-10 | Fortgesetzt | BTIG Research | Buy |
| 2018-05-31 | Eingeleitet | Evercore ISI | Outperform |
| 2018-03-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-03-31 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Macrogenics Inc Aktie (MGNX) Neueste Nachrichten
MacroGenics Inc Stock (US5562221046): Valuation metrics in focus after recent biotech swing - AD HOC NEWS
How The MacroGenics (MGNX) Story Is Shifting With ADC Pipeline Bets And 2026 Data Risks - Yahoo Finance
Millennium Group and Israel Englander report 3.44M MGNX shares (5.4%) - Stock Titan
MacroGenics eyes $200M cash boost, 2028 runway ahead of cancer pipeline updates - MSN
MacroGenics expands ZYNYZ royalty deal with Sagard, secures $60M upfront - MSN
MacroGenics Inc stock (US5562221046): shares ease after strong year-to-date run amid biotech volatil - AD HOC NEWS
Will MacroGenics (MGNX) report negative Q1 earnings? What you should know - MSN
Macrogenics(MGNX) Stock Options Chain | Quotes & News - Moomoo
MacroGenics, Inc. (MGNX) Latest Stock News & Headlines - Yahoo Finance
MacroGenics Eyes $200M Cash Boost, 2028 Runway Ahead of Cancer Pipeline Updates - TradingView
MacroGenics, Inc. Hits New 52-Week High of $4.64 - Markets Mojo
MacroGenics to sell manufacturing operations to Bora for $122.5M - MSN
MacroGenics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
How The MacroGenics (MGNX) Story Is Shifting With ADC Hopes And Execution Risks - Yahoo Finance
MacroGenics stock (US5562221046): insider equity grants follow 2026 shareholder meeting - AD HOC NEWS
MacroGenics Shareholders Back Board, Auditors and Equity Plan - TipRanks
MACROGENICS (MGNX) director O'Brien receives RSUs and 22,000-share option grant - Stock Titan
MacroGenics (MGNX) director receives new options and RSU awards - Stock Titan
MacroGenics (MGNX) director granted options, RSUs and stock - Stock Titan
MacroGenics (MGNX) director converts 3,750 RSUs into common shares - Stock Titan
MacroGenics (MGNX) director awarded options, RSUs and exercises prior grant - Stock Titan
MACROGENICS (MGNX) director Meenu Chhabra gets RSUs, options and RSU vesting - Stock Titan
MACROGENICS (MGNX) director granted options, RSUs and exercises awards - Stock Titan
MACROGENICS (MGNX) director David C. Stump gets new options and RSUs - Stock Titan
MacroGenics (MGNX) director granted options and RSUs, RSUs vest into shares - Stock Titan
MacroGenics (MGNX) awards stock options and RSUs to director Koenig - Stock Titan
MacroGenics (MGNX) investors back board slate and expand 2023 equity plan - Stock Titan
MacroGenics stock (US5562221046): biotech shares jump after Vyloy FDA approval and takeover deal - AD HOC NEWS
MacroGenics appoints new CEO - MSN
Macrogenics (MGNX) News Flow - Moomoo
MacroGenics stock (US5562221046): FDA hold lifted and shares among May’s biotech gainers - AD HOC NEWS
MacroGenics (MGNX) price target increased by 50.00% to 6.12 - MSN
MacroGenics gains removal of FDA partial hold on lead program - MSN
Bora Group to acquire MacroGenics manufacturing for 122.5 million - MSN
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Beha - GuruFocus
Bora to acquire MacroGenics‘ biologics manufacturing facility in Maryland - megaproject.com
MacroGenics sells manufacturing arm to Bora in $123m deal - The Pharma Letter
MacroGenics, Inc.Common Stock (NQ: MGNX - The Chronicle-Journal
Armistice Capital (MGNX) reports 6.01M-share, 9.46% stake in Macrogenics - Stock Titan
MacroGenics, Inc. (NASDAQ:MGNX) Analysts Are Pretty Bullish On The Stock After Recent Results - Yahoo Finance
MacroGenics Reaches US$219m Market Cap Benefiting Insider Stock Buying - Moomoo
Millennium Group reports 3.07M-share stake in MacroGenics (MGNX) - Stock Titan
Bank of America (NASDAQ: MGNX) reports 5.1% ownership in MacroGenics - Stock Titan
MacroGenics to Participate in the Stifel 2026 Virtual Targeted Oncology Forum - The Manila Times
Macrogenics Cash, Cash Equivalents and Marketable Securities Balance of $154.2 M as of March 31 >MGNX - Moomoo
Stifel Maintains Macrogenics(MGNX.US) With Hold Rating, Maintains Target Price $4 - Moomoo
Bora Pharmaceuticals to Acquire MacroGenics Manufacturing Facility in $122.5 Million Deal - biobuzz.io
Barclays Maintains Macrogenics(MGNX.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Key facts: MacroGenics Q1 +58% revenue; $36.8M loss; LINNET 4 responses - TradingView
Is MacroGenics (MGNX) 10.6% Undervalued After Q1 2026 Beat? EPS - GuruFocus
MacroGenics (MGNX) reports Q1 loss, tops revenue estimates - MSN
Finanzdaten der Macrogenics Inc-Aktie (MGNX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Macrogenics Inc-Aktie (MGNX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| HEIDEN WILLIAM K | Director |
Aug 19 '25 |
Buy |
1.52 |
50,500 |
76,760 |
61,500 |
| HEIDEN WILLIAM K | Director |
Aug 20 '25 |
Buy |
1.49 |
49,500 |
73,755 |
111,000 |
| Koenig Scott | Director |
Aug 13 '25 |
Option Exercise |
0.00 |
52,829 |
0 |
830,244 |
2.60%
0.94%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):